- Home
- SCYX vs RADX Comparison
SCYX vs RADX Comparison
Compare SCYX & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- RADX
- Stock Information
- Founded
- SCYX 1999
- RADX 2021
- Country
- SCYX United States
- RADX Australia
- Employees
- SCYX N/A
- RADX N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- RADX
- Sector
- SCYX Health Care
- RADX
- Exchange
- SCYX Nasdaq
- RADX NYSE
- Market Cap
- SCYX 36.8M
- RADX 32.5M
- IPO Year
- SCYX 2014
- RADX N/A
- Fundamental
- Price
- SCYX $0.74
- RADX $4.70
- Analyst Decision
- SCYX
- RADX Strong Buy
- Analyst Count
- SCYX 0
- RADX 2
- Target Price
- SCYX N/A
- RADX $13.50
- AVG Volume (30 Days)
- SCYX 170.9K
- RADX 21.1K
- Earning Date
- SCYX 08-07-2025
- RADX 02-26-2025
- Dividend Yield
- SCYX N/A
- RADX N/A
- EPS Growth
- SCYX N/A
- RADX N/A
- EPS
- SCYX N/A
- RADX N/A
- Revenue
- SCYX $2,630,000.00
- RADX $204,609.00
- Revenue This Year
- SCYX $463.61
- RADX N/A
- Revenue Next Year
- SCYX $310.80
- RADX N/A
- P/E Ratio
- SCYX N/A
- RADX N/A
- Revenue Growth
- SCYX N/A
- RADX N/A
- 52 Week Low
- SCYX $0.72
- RADX $3.50
- 52 Week High
- SCYX $2.29
- RADX $50.82
- Technical
- Relative Strength Index (RSI)
- SCYX 37.94
- RADX N/A
- Support Level
- SCYX $0.72
- RADX N/A
- Resistance Level
- SCYX $0.85
- RADX N/A
- Average True Range (ATR)
- SCYX 0.05
- RADX 0.00
- MACD
- SCYX -0.01
- RADX 0.00
- Stochastic Oscillator
- SCYX 9.61
- RADX 0.00
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.